TCON - TRACON Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.7400
+0.0400 (+5.71%)
As of 2:24PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.7000
Open0.7200
Bid0.7291 x 1200
Ask0.7400 x 1300
Day's Range0.6700 - 0.7643
52 Week Range0.5000 - 2.8000
Volume519,760
Avg. Volume291,862
Market Cap22.154M
Beta (3Y Monthly)2.90
PE Ratio (TTM)N/A
EPS (TTM)-1.1320
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • What Kind Of Shareholders Own TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)?
    Simply Wall St.18 days ago

    What Kind Of Shareholders Own TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)?

    A look at the shareholders of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) can tell us which group is most powerful...

  • GlobeNewswire26 days ago

    TRACON Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

    SAN DIEGO, May 30, 2019 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of TCON earnings conference call or presentation 14-May-19 8:30pm GMT

    Q1 2019 TRACON Pharmaceuticals Inc Earnings Call

  • Associated Presslast month

    Tracon: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 24 cents per share. In the final minutes of trading on Tuesday, the company's shares hit 68 cents. A year ago, they were trading at $2.45. _____ This story ...

  • GlobeNewswirelast month

    TRACON Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen Pharmaceutical Co. Ltd., wet age‐related macular degeneration, today announced financial results for the first quarter ended March 31, 2019. “While we were disappointed in the outcome of the TAPPAS interim analysis, we have several other active clinical programs and look forward to developing multiple bispecific antibodies through our broad and long term partnership with I-Mab Biopharma,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON.

  • ACCESSWIRElast month

    TRACON Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2019 / TRACON Pharmaceuticals, Inc. (NASDAQ: TCON ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 4:30 ...

  • GlobeNewswire2 months ago

    TRACON to Report First Quarter 2019 Company Highlights and Financial Results on May 14, 2019

    SAN DIEGO, May 07, 2019 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted.

  • Bad news for Apple, Tracon slides, Boeing completes test flights
    Yahoo Finance2 months ago

    Bad news for Apple, Tracon slides, Boeing completes test flights

    Apple, Tracon, Boeing and J.Crew are the companies to watch.

  • MarketWatch2 months ago

    Tracon Pharmaceuticals shares slide 45% premarket after it ends trial of cancer treatment

    Tracon Pharmaceuticals Inc. shares slid 45% in premarket trade Friday, after the cmpany said it is terminating a late-stage trial of a cancer treatment at the recommendation of an independent committee. The company said its phase 3 trial evaluating TRC105 in combination with Votrient in patients with advanced or metastatic angiosarcoma, a rare kind of cancer, was terminated for futility based on the recommendation of the Independent Data Monitoring Committee following a review of data from more than 120 patients. "We are disappointed that TRC105 in combination with Votrient did not demonstrate clinically meaningful efficacy in patients with advanced or metastatic angiosarcoma," Tracon Chief Executive Charles Theuer said in a statement. The company will continue to develop other drug candidates and has enough cash to extend to the third quarter of 2020, he said. TRC105 is a clinical stage antibody to endoglin, a protein that is essential for angiogenesis, the process of new blood vessel formation. Tracon shares have fallen 55% in the 12 months through Thursday, while the S&P 500 has gained 8.4%.

  • GlobeNewswire2 months ago

    TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial Based on the Recommendation of the Independent Data Monitoring Committee

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and, through our license to Santen Pharmaceutical Co. Ltd., wet age-related macular degeneration, today announced that its Phase 3 TAPPAS trial evaluating TRC105 in combination with Votrient (pazopanib) in patients with advanced or metastatic angiosarcoma was terminated for futility based on the recommendation of the Independent Data Monitoring Committee (IDMC) following its review of interim unblinded safety and efficacy data from more than 120 patients enrolled in the trial at the time of the analysis. TRACON will work with investigators to appropriately conclude the study in a manner consistent with the best interests of each patient.

  • GlobeNewswire3 months ago

    TRACON Pharmaceuticals Announces TRC105, TRC253 and TRC102 Data Presentations at Upcoming AACR Annual Meeting

    SAN DIEGO, March 27, 2019 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted.

  • How Should Investors React To TRACON Pharmaceuticals, Inc.’s (NASDAQ:TCON) CEO Pay?
    Simply Wall St.4 months ago

    How Should Investors React To TRACON Pharmaceuticals, Inc.’s (NASDAQ:TCON) CEO Pay?

    Charles Theuer has been the CEO of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) since 2006. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growthRead More...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of TCON earnings conference call or presentation 28-Feb-19 9:30pm GMT

    Q4 2018 TRACON Pharmaceuticals Inc Earnings Call

  • GlobeNewswire4 months ago

    TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen Pharmaceutical Co. Ltd., wet age‐related macular degeneration, today announced financial results for the fourth quarter and year ended December 31, 2018. In February, we began preparation of data tables for the interim analysis by the Independent Data Monitoring Committee (DMC), following enrollment of the 120th patient into the TAPPAS Phase 3 trial.

  • GlobeNewswire4 months ago

    TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019

    SAN DIEGO, Feb. 21, 2019 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted.

  • GlobeNewswire5 months ago

    TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that positive clinical data from its ongoing Phase 1b/2 study of TRC105 and Nexavar® (sorafenib) in patients with advanced hepatocellular carcinoma (HCC) were presented in a poster presentation at the ASCO 2019 Gastrointestinal Cancers Symposium in San Francisco on January 18, 2019. Data from the ongoing open-label, non-randomized study were presented by Dr. Kanwal Raghav from the University of Texas MD Anderson Cancer Center.

  • GlobeNewswire6 months ago

    Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Dec. 31, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE6 months ago

    Stocks to Watch Before The Opening Bell on December 27, 2018

    CORAL GABLES, FL / ACCESSWIRE / December 27, 2018 / This year has been nothing short of exciting for the stock market, with swings occurring almost regularly. As 2019 rears its head, Premier Health Group (OTC:PHGRF) (CSE:PHGI), TRACON Pharmaceuticals Inc (TCON), Energous Corp (WATT), and Amira Nature Foods Ltd (ANFI) are 4 stocks that may present potential opportunities just in time for the new year. Premier Health Group (OTC:PHGRF) (CSE:PHGI) has seen a strong period of bullish trading this past month following multiple announcements regarding key agreements that continue to spark investor interest in the healthcare sector.

  • Benzinga6 months ago

    The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 26) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Down In The ...

  • GlobeNewswire6 months ago

    TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced positive top-line clinical results from a Phase 1 study of TRC105 and Opdivo® (nivolumab) for the treatment of non-small cell lung cancer. In this Phase 1b trial, patients with refractory metastatic non-small cell lung cancer were enrolled regardless of baseline PD-L1 tumor expression.  Patients were treated with 8 mg/kg or 10 mg/kg of TRC105 weekly for four doses and then 15 mg/kg every two weeks, in combination with the approved dose of Opdivo of 240 mg every two weeks.  Best response was assessed by immune RECIST 1.1.

  • GlobeNewswire6 months ago

    TRACON Pharmaceuticals Announces Submission of IND Application for TJ4309 (CD73 Antibody TJD5) for Treatment of Advanced Solid Tumors

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today announced that TRACON has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical study of TJ4309 in patients with advanced solid tumors. TJ4309, also known as TJD5, is a CD73 antibody from I-Mab’s proprietary discovery pipeline that is being co-developed through an agreement between TRACON and I-Mab that was signed on November 28, 2018.  The agreement between the two companies is part of a broad strategic partnership to develop multiple immuno-oncology programs with first-in-class and best-in-class potential from I-Mab’s immuno-oncology portfolio, including several proprietary bispecific antibodies under development by I-Mab.

  • GlobeNewswire6 months ago

    TRACON Pharmaceuticals Announces Top-line Data from Phase 2 TRAXAR Clinical Trial in Renal Cell Carcinoma

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that its Phase 2 TRAXAR trial evaluating TRC105 in combination with Inlyta (axitinib) in patients with advanced or metastatic renal cell carcinoma did not meet the primary endpoint of improving progression free survival (PFS) in the intent to treat population compared to Inlyta monotherapy. TRACON will work with investigators to appropriately conclude the study in a manner consistent with the best interests of each patient. “We are disappointed that TRC105 in combination with Inlyta did not demonstrate clinically meaningful efficacy in patients with advanced or metastatic renal cell carcinoma.

  • GlobeNewswire7 months ago

    TRACON Pharmaceuticals and I-Mab Biopharma Reschedule Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs

    Due to the United States stock markets being closed on Wednesday, December 5, 2018, for the national day of mourning due to the passing of President George H. W. Bush, TRACON Pharmaceuticals (TCON), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and I-Mab Biopharma (“I-Mab”), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, have rescheduled their conference call and webcast to Thursday, December 6, 2018, to discuss the recently announced series of strategic collaborative partnerships for developing multiple immuno-oncology programs. TRACON develops targeted therapies for cancer and ophthalmic diseases.

  • GlobeNewswire7 months ago

    TRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and I-Mab Biopharma (“I-Mab”), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, will host a conference call and webcast on Wednesday, December 5, 2018, to discuss the recently announced series of strategic collaborative partnerships for developing multiple immuno-oncology programs. TRACON develops targeted therapies for cancer and ophthalmic diseases.